Product information and disease descriptionPlace of product in therapyApproaches to treatment
Expected outcomes of therapy
6 evidence topics · 6 sources
Sponsor-stated goal: one-time treatment of the genetic cause
Pivotal efficacy threshold: developmental milestone response rate
REVEAL Part A: functional gains over 12 or more months
Caregiver-defined meaningful outcomes of gene therapy
Uncertainty: durability, long-term safety, and clinically meaningful benefit
“Determining what constitutes clinically meaningful benefit is equally difficult; families report that even modest gains in independence, communication, or daily living skills are profoundly valuable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because gene therapy aims to deliver lifelong MeCP2 expression, long-term safety remains largely unknown. Open questions include durability of expression, feasibility of re-dosing in the context of anti-AAV immunity, potential for delayed toxicity from MeCP2 overexpression, risk of chronic CNS immune responses, and the theoretical possibility of insertional mutagenesis despite low AAV integration rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Addressing these uncertainties will require decades-long surveillance; current protocols mandate 15-year follow-up for all treated individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote